Status: Recruiting
Neoadjuvant Personalized Anti-PD-1 and Anti-VEGFR Therapy in OSCC Patients
To evaluate the efficacy of neoadjuvant anti-PD-1 plus anti-VEGFR therapy for patients with locally advanced and resectable oral squamous cell carcinoma, and the CPS\>10 in the biopsy samples.
Participants needed: 46
Trial details
Phase: Phase 2Age: 18-75Biological sex: AllType: InterventionalSponsor: Shanghai Jiao Tong University School of MedicineUpdated: Nov 22, 2023Locations: 1
Eligibility criteria
Age: 18 to 75 [+6]
Toxicity of ≥ grade 2 (CTCAE 5.0) that has not subsided due to previous anticanc... [+10]